Advanced Accelerator Applications (AAA) is a French biotechnology company that develops and commercializes radiopharmaceuticals for the treatment of cancer. The company is headquartered in Paris, France, and is a subsidiary of Novartis following its acquisition in 2018.
History
- 2002 – AAA was founded as a spin‑off from the French Atomic Energy Commission (CEA) to focus on the development of molecular radiotherapy agents.
- 2014 – The company completed its initial public offering (IPO) on Euronext Paris, raising capital to advance its clinical pipeline.
- 2018 – Novartis announced the acquisition of AAA for approximately €3.9 billion (€3.5 billion in cash and €400 million in Novartis shares). The transaction closed in September 2018, and AAA was integrated into Novartis Oncology.
Product Portfolio
- Lutathera® ([^177Lu]Lu‑DOTATATE) – The first radioligand therapy approved in the European Union (2017) and the United States (2018) for the treatment of somatostatin‑receptor‑positive gastro‑enteropancreatic neuroendocrine tumors (GEP‑NETs).
- ^68Ga‑Dotatate – A diagnostic imaging agent used with positron emission tomography (PET) for detecting neuroendocrine tumors.
- Additional investigational products in AAA’s pipeline target prostate‑specific membrane antigen (PSMA) and other tumor‑associated antigens, employing ^177Lu or ^225Ac radionuclides.
Scientific Approach
AAA’s research combines molecular targeting with radionuclide therapy, creating “theranostics” that pair a diagnostic radiopharmaceutical (e.g., ^68Ga‑labeled) with a therapeutic counterpart (e.g., ^177Lu‑labeled) to enable patient selection, treatment planning, and response monitoring.
Regulatory Milestones
- 2017 – European Medicines Agency (EMA) granted marketing authorization for Lutathera®.
- 2018 – U.S. Food and Drug Administration (FDA) approved Lutathera® under the brand name Lutathera™.
- Ongoing clinical trials are conducted under the oversight of national and international regulatory agencies to evaluate safety and efficacy of additional candidates.
Corporate Structure
Following the Novartis acquisition, AAA operates as part of Novartis Oncology’s Global Development division. Its workforce includes experts in radiochemistry, nuclear medicine, pharmacology, and clinical development.
Impact
Advanced Accelerator Applications has been credited with pioneering the clinical adoption of radioligand therapy in oncology, contributing to the expanding field of precision medicine that integrates diagnostic imaging and targeted radionuclide treatment.
